Publications by authors named "Motoki Yamagishi"
Background/aim: Although multiple treatments are available for metastatic castration-resistant prostate cancer, data to determine the optimal treatment sequence are limited. This study aimed to investigate the current status of drug therapy for castration-resistant prostate cancer and clarify the sequential treatment in actual clinical practice.
Patients And Methods: This retrospective study included 425 patients diagnosed with castration-resistant prostate cancer at Showa University Hospital and affiliated hospitals between January 2014 and December 2021, who were treated with any of the following four drugs: novel androgen receptor signal inhibitors (abiraterone acetate and enzalutamide) and anticancer drugs (docetaxel and cabazitaxel).
Introduction: Urethral hemangioma is an extremely rare occurrence and is not typically considered a common cause of hematuria. Since 2000, only 22 male cases have been reported.
Case Presentation: A 45-year-old man presented with recurrent painless gross hematuria and the passage of blood clots after ejaculation.
Objective: Demand for erectile dysfunction treatments has increased not only in elderly patients but also in young patients. Reports indicate that frequent causes of erectile dysfunction in Japan are organic disorders in elderly patients and psychogenetic disorders in young patients.
Methods: We defined patients under the age of 40 as young erectile dysfunction patients, and those over 65 as elderly erectile dysfunction patients.
[INITIAL TREATMENT OF NOCTURIA CAUSED BY NOCTURNAL POLYURIA WITH LOW-DOSE DESMOPRESSIN].
Nihon Hinyokika Gakkai Zasshi
January 2022
(Objective) Nocturia, an important male lower urinary tract symptom (LUTS), is often difficult to treat. Herein, we report our experience of the initial treatment of nocturia with the novel drug desmopressin. (Subjects and methods) Subjects included 25 patients with LUTS treated with desmopressin who had the chief complaint of nocturia.
View Article and Find Full Text PDFIntroduction: Combination chemotherapy of gemcitabine and cisplatin (GC) is the standard treatment for patients with urothelial cancer (UC). However, hematological toxicity is a major side effect of GC therapy in patients with UC. In particular, discontinuation of the GC therapy is associated to adverse events such as hematological toxicity.
View Article and Find Full Text PDFArticle Synopsis
- A case study of a 52-year-old woman reveals her struggles with hypertension and diabetes, which worsened over time despite treatment.
- After developing symptoms like headaches and palpitations, imaging studies identified a 4-cm mass in her left adrenal gland linked to elevated catecholamine levels.
- Post-rupture, significant changes were noted in imaging and hormone levels, leading to a diagnosis of pheochromocytoma confirmed by histopathological examination of the resected tumor, which showed signs of hemorrhagic necrosis.
[INITIAL EXPERIENCE OF THE ENZALUTAMIDE TREATMENT FOR CASTRATION-RESISTANT PROSTATE CANCER].
Nihon Hinyokika Gakkai Zasshi
January 2016
Article Synopsis
- Enzalutamide is an oral medication that helps prolong survival in men with castration-resistant prostate cancer (CRPC) and was evaluated for its effectiveness and safety in a study of 73 patients.
- The study found that patients without prior docetaxel treatment had a better response to enzalutamide, with 61.4% achieving a significant reduction in PSA levels, compared to only 24.1% in those who had received docetaxel.
- Common side effects included fatigue, anorexia, and nausea, and some patients experienced a PSA flare, which can occur in those who respond to treatment.